Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
Authors
Keywords
-
Journal
Cancer Medicine
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-07-04
DOI
10.1002/cam4.2375
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
- (2018) Yi-Mi Wu et al. CELL
- Immunological and genomic correlates of response to anti-PD1 checkpoint therapy in mismatch proficient and deficient patients with metastasized castration resistant prostate cancer.
- (2018) Minke Smits et al. JOURNAL OF CLINICAL ONCOLOGY
- The long tail of oncogenic drivers in prostate cancer
- (2018) Joshua Armenia et al. NATURE GENETICS
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab (Pembro) plus enzalutamide (Enz) in metastatic castration resistant prostate cancer (mCRPC): Extended follow up.
- (2018) Julie Nicole Graff et al. JOURNAL OF CLINICAL ONCOLOGY
- KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
- (2018) Johann S. De Bono et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
- (2016) Julie N. Graff et al. Oncotarget
- Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
- (2016) D. B. Johnson et al. Cancer Immunology Research
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
- (2015) Jennifer L. Bishop et al. Oncotarget
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer
- (2014) Colin C. Pritchard et al. Nature Communications
- Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer
- (2013) Guru Sonpavde et al. BJU INTERNATIONAL
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now